Business Wire

BYNDER

Share
Bynder Acquires EMRAYS to Revolutionize DAM User Experience With AI-Powered Innovation

Bynder, the market-leading digital asset management (DAM) platform has today announced the acquisition of EMRAYS, a specialist provider of AI search solutions for DAM.

The acquisition further elevates Bynder’s widely recognised user experience and will improve asset findability for Bynder DAM users. It builds on Bynder’s existing investments in AI and reaffirms the company’s commitment to helping customers conquer the complexity and chaos of proliferating content with the most powerful, intuitive, and richly integrated DAM platform.

With these new capabilities, DAM admins can reduce or eliminate the time and effort needed to manage assets, reduce costs associated with management of their DAM, while improving the speed and relevancy associated with the discovery of assets. EMRAYS enables Bynder customers to further benefit from their market leading user experience, building on their market leading user adoption, especially in large enterprise deployments.

EMRAYS was an existing partner whose technology was built specifically for Bynder DAM. The technology is already adopted within a number of customer accounts and is helping these brands to deliver even better content experiences to their customers.

For brands grappling with the challenges of managing content at scale, EMRAYS similarity search, search by image, text in image search, and duplicate finder impacts the heart of their content operations, allowing teams to find, reuse and deliver more relevant content, quicker and more effectively.

Siemens Healthineers use the Bynder DAM platform across 30,000 users, and already benefit from EMRAYS capabilities. André Kögler, Head of Digital Strategy & Tools, Creative Services said: “EMRAYS AI search enables us to find images and content faster, improving efficiency in our processes. In addition, the enhanced organization features help ensure the content in our Bynder DAM is consistent and high quality.”

Bob Hickey, CEO of Bynder, said: “We are excited to be welcoming the EMRAYS team to Bynder. This announcement comes off the back of recent investments in bringing generative AI capabilities to market.

“Marketing teams across the globe continue to be challenged with the need to manage and distribute a growing volume of targeted content. The acquisition of EMRAYS will help our customers automate the management of this. Like many of our recent AI developments, this acquisition is further proof of Bynder’s commitment to continued innovation and market leadership in the DAM category. The combination of product and people will enable us to accelerate our AI roadmap and deliver additional value to our customers faster.”

Cliff Crosbie, CEO and Co-Founder of EMRAYS said: “AI within DAM has become a strategic ally for marketers seeking to streamline content operations and improve customer experiences. The interest and demand we’ve had from customers to implement our AI technology within the Bynder platform has fueled this partnership and subsequent acquisition. The value that customers receive from EMRAYS capabilities already is invaluable, as marketers overcome content creation challenges and achieve greater efficiency.

“We’re excited about this acquisition and look forward to innovating with Bynder on their AI roadmap.”

For more information on Bynder and its AI capabilities, please visit https://www.bynder.com/en/solutions/initiatives/ai-automation/

-ENDS-

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230919301251/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting konsoliderer sit udbud inden for digital transformation med tilføjelsen af Internet & Idee22.1.2026 14:04:00 CET | Pressemeddelelse

Andersen Consulting indgår en samarbejdsaftale med Internet & Idee, et italiensk digitalt konsulentbureau, og styrker dermed sin evne til at levere integrerede, teknologidrevne løsninger. Internet & Idee blev stiftet i 1998 og specialiserer sig i digital strategi, softwareudvikling, test og kvalitetssikring, e-handel og mobile løsninger. Virksomheden opererer inden for to kerneområder: It-konsulentydelser og egne SaaS-produkter, herunder værktøjer til kreditstyring og cybersikkerhed. Med dyb ekspertise inden for bankvæsen, forsikring, kreditstyring og logistik for e-handel kombinerer Internet & Idee brancheindsigt med teknisk innovation med henblik på at drive forretningsresultater. "Dette samarbejde giver os mulighed for at anvende vores digitale ekspertise og branchekendskab i større skala," udtaler Carlo Stumpo, administrerende direktør for Internet & Idee. "Sammen med Andersen Consulting kan vi levere mere målrettede og effektive løsninger til kunder, der står over for komplekse ud

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press release

Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant’s Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitax

ExaGrid Announces All Flash/SSD Tiered Backup Storage Solution22.1.2026 14:00:00 CET | Press release

ExaGrid’s new solution offers the fastest, most scalable, and most secure backups in the industry ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it is shipping an All Flash/SSD backup storage solution with a unique front-end Landing Zone and non-network-facing Repository Tier (tiered air gap) that stores all backup retention using advanced data deduplication. The new SSD appliances ship with ExaGrid software version 8. ExaGrid’s unique Landing Zone and scale-out architecture allow for significantly faster backups and restores, as well as scalability as data grows, versus other SSD products such as Dell Data Domain inline deduplication appliances with SSD or straight SSD from Pure Storage. Due to three years of software work and the extremely fast performance of SSD, ExaGrid’s

Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis22.1.2026 14:00:00 CET | Press release

New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers. Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by provi

AMGTA Announces EOS as New Principal Member and Appoints Björn Hannappel to Board of Directors22.1.2026 13:59:00 CET | Press release

The Additive Manufacturer Green Trade Association (AMGTA) today announced that EOS has elevated its longstanding participation in the association to Principal Member. As part of this expanded leadership role, Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121601881/en/ Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. Principal Membership represents AMGTA’s highest level of engagement and is reserved for organizations demonstrating sustained leadership, strategic alignment, and a commitment to advancing sustainable and resilient manufacturing practices globally. As a Principal Member, EOS will take on an expanded role in shaping AMGTA’s strategic direction, governance, and industry collaboration initiatives. EOS is a world-leading technology supplier in the field of commercial 3D printing of meta

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye